Changing the Standard of Care in the M0 CRPC Patient: PROSPER - A Conversation with Cora Sternberg

March 25, 2018

(Length of conversation: 11 min)
Cora Sternberg, MD and Alicia Morgans, MD explore the importance of the study results from Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER).  The purpose of this study was to assess the safety and efficacy of enzalutamide in patients with non metastatic (M0) prostate cancer.  Dr. Sternberg discusses the PROSPER study design, the global impact of the study findings on clinical practice, clarification on the safety data and the benefit of treating the prostate cancer patient earlier in their disease for overall survival benefit. 
View PDF Version of PROSPER EAU Slide Presentation - Cora Sternberg
View RESULTS from PROSPER EAU 2018 Poster 
Dr. Cora Sternberg is chief of the Department of Medical Oncology at the San Camillo-Forlanini Hospital in Rome, Italy. She has attained the rank of full Professor of Oncology and is an adjunct professor at La Sapienza University in Rome. She is also adjunct professor of Urology and Urological Oncology at Tufts University School of Medicine and the Lahey Clinic in Boston, Massachusetts, and adjunct professor at Temple University’s College of Science and Technology in Philadelphia, Pennsylvania. A graduate of the University of Pennsylvania undergraduate and medical schools, she completed her fellowship and was on staff at Memorial Sloan Kettering Cancer in NY. Dr. Sternberg is an internationally respected leader in the fields of medical oncology and urological malignancies and a recognized expert in the area of new drug development. She is the principal investigator for numerous studies and an internationally respected researcher who has lectured extensively at universities and cancer symposia worldwide. Dr. Sternberg is particularly known for her influential work in bladder cancer and for her publications on novel therapies for prostate cancer and targeted agents in renal cell carcinoma. Dr. Sternberg has published extensively (more than 375 articles, 6 textbooks) and is an associate editor and editorial board member of several International journals. European School of Oncology (ESO) core faculty and in tune with American medicine, Dr. Sternberg has been elected for a 3-year term to the nominating committee of ASCO’s board of directors.

Alicia Morgans, MD.